Education
About Us
Working with TipRanks
Follow Us
Cormorant Asset Management, LLC Insider Profile
18 Followers
Cormorant Asset Management, LLC, Ten Percent Owner at Cellectar Biosciences, holds 1.81M shares in OnKure Therapeutics (Ticker: OKUR), holds 1.63M shares in BioAge Labs, Inc. (Ticker: BIOA), holds 2.38M shares in Corbus Pharmaceuticals (Ticker: CRBP). Most recently, Cormorant Asset Management, LLC Sold ― shares of OnKure Therapeutics on May 14, 2025 for an estimated value of 48.11K.
Cormorant Asset Management, LLC Cellectar Biosciences (CLRB)Ten Percent Owner
Cellectar Biosciences (CLRB)
Ten Percent Owner
Ranked #98,566 out of 101,378 Corporate Insiders
Profitable Transactions
8 out of 40 Profitable Transactions
Average Return
-34.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Cormorant Asset Management, LLC's holdings
Insider Roles
Roles that Cormorant Asset Management, LLC holds in companies
Most Profitable Insider Trade
Stock:
Ambrx Biopharma
(AMAM)
(AMAM)
Rating:Informative Buy
Date:Mar 16, 2023 - Mar 16, 2024
Return:+176.40%
The most profitable trade made by Cormorant Asset Management, LLC
Cormorant Asset Management, LLC's Trading History
Cellectar Biosciences
Sep 05, 2014
Ten Percent Owner
Informative Buy
―
$134.09K
Kineta
Dec 18, 2017
Ten Percent Owner
Informative Buy
2.46M
$924.00K
Kiniksa Pharmaceuticals
May 31, 2018
Ten Percent Owner
Informative Buy
1.25M
$44.79M
Kezar Life Sciences
Jun 27, 2018
Ten Percent Owner
Informative Buy
3.75M
$7.67M
Axonics Modulation Technologies
Nov 02, 2018
―
Informative Buy
2.00M
$133.86M
Turning Point Therapeutics
Apr 25, 2019
―
Informative Buy
7.20M
$237.33M
Avidity Biosciences
Jun 18, 2020
Former 10% Owner
Informative Buy
5.40M
$72.85M
Atea Pharmaceuticals
Nov 05, 2020
Former 10% Owner
Uninformative Buy
―
$16.61M
Olema Pharmaceuticals
Nov 23, 2020
Former 10% Owner
Uninformative Buy
―
$15.34M
BioAtla
Dec 22, 2020
Former 10% Owner
Uninformative Buy
―
$981.00K
Prometheus Biosciences
Mar 18, 2021
―
Uninformative Buy
―
$444.43M
Design Therapeutics
Apr 01, 2021
Former 10% Owner
Uninformative Buy
―
$17.19M
Biomea Fusion
―
Director, Ten Percent Owner
―
―
Rain Oncology
Apr 29, 2021
―
Uninformative Buy
―
$3.36M
Verve Therapeutics
Jun 23, 2021
Former 10% Owner
Uninformative Buy
―
$4.25M
Jade Biosciences
Jul 07, 2021
Former 10% Owner
Uninformative Buy
―
$15.03M
Elevation Oncology
Jul 01, 2021
Former 10% Owner
Uninformative Buy
―
$667.72K
Monte Rosa Therapeutics
Jun 30, 2021
Former 10% Owner
Informative Buy
11.40M
$12.39M
Icosavax
Aug 04, 2021
―
Uninformative Buy
―
$6.53M
Immuneering
Apr 03, 2024
Ten Percent Owner
Informative Sell
1.16M
$3.72M
Tyra Bioscience
Sep 21, 2021
Former 10% Owner
Uninformative Buy
―
$10.55M
Pyxis Oncology
Oct 15, 2021
Former 10% Owner
Uninformative Buy
―
$1.24M
Ventyx Biosciences
Oct 27, 2021
Former 10% Owner
Uninformative Buy
―
$1.71M
Vigil Neuroscience Inc
Jan 13, 2022
Former 10% Owner
Uninformative Buy
―
$1.43M
Ambrx Biopharma
Oct 25, 2023
―
Informative Buy
9.14M
$314.47M
GreenLight Biosciences Holdings
Jul 24, 2023
―
Uninformative Sell
―
$0.00
EyePoint Pharmaceuticals
May 08, 2024
Ten Percent Owner
Informative Buy
10.08M
$47.62M
Corbus Pharmaceuticals
Sep 24, 2024
Ten Percent Owner
Informative Buy
7.00M
$17.12M
BioAge Labs, Inc.
Oct 01, 2024
Former 10% Owner
Uninformative Buy
―
$6.22M
OnKure Therapeutics
May 14, 2025
Ten Percent Owner
Informative Sell
48.11K
$3.74M
List of latest transactions for each holding click on a transaction to see Cormorant Asset Management, LLC's performance on stock
You May Also Like
Cormorant Asset Management, LLC insider profile FAQ
What is the percentage of profitable transactions made by Cormorant Asset Management, LLC?
The percentage of profitable transactions made by Cormorant Asset Management, LLC is 20%.
What is the average return per transaction made by Cormorant Asset Management, LLC?
The average return per transaction made by Cormorant Asset Management, LLC is -34.20%.
What stocks does Cormorant Asset Management, LLC hold?
Cormorant Asset Management, LLC holds: CLRB, KANT, KNSA, KZR, AXNX, TPTX, RNA, AVIR, OLMA, BCAB, RXDX, DSGN, BMEA, RAIN, VERV, JBIO, ELEV, GLUE, ICVX, IMRX, TYRA, PYXS, VTYX, VIGL, AMAM, GRNA, EYPT, CRBP, BIOA, OKUR stocks.
What was Cormorant Asset Management, LLC’s latest transaction?
Cormorant Asset Management, LLC latest transaction was an Informative Sell of $48.11K.
What was Cormorant Asset Management, LLC's most profitable transaction?
Cormorant Asset Management, LLC’s most profitable transaction was an Informative Buy of AMAM stock on March 16, 2023. The return on the trade was 176.40%.
What is Cormorant Asset Management, LLC's role in Cellectar Biosciences?
Cormorant Asset Management, LLC's role in Cellectar Biosciences is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.